David Carew and Hugh Robert Holmes, individually and on behalf of all others similarly situated v. LifeCore Biomedical, Inc.; Albert D. Bolles; James G. Hall; Brian McLaughlin; and John Morberg

District Court, D. Minnesota·Decided August 6, 2026·No. 0:24-cv-03028·Unknown

Opinion

fcUNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA

DAVID CAREW and HUGH ROBERT Case No. 24-cv-3028 (LMP/EMB) HOLMES, individually and on behalf of all others similarly situated,

Plaintiffs, ORDER APPROVING CLASS v. ACTION SETTLEMENT AND AWARDING LIFECORE BIOMEDICAL, INC.; ATTORNEYS’ FEES, EXPENSES, ALBERT D. BOLLES; JAMES G. AND SERVICE AWARDS HALL; BRIAN McLAUGHLIN; and JOHN MORBERG,

Defendants.

Robert K. Shelquist, Cuneo Gilbert Flannery & LaDuca LLP, St. Louis Park, MN, Jeremy A. Lieberman, Brenda Szydlo, and Dean P. Ferrogari, Pomerantz LLP, New York, NY, Phillip Kim and Ha Sung (Scott) Kim, The Rosen Law Firm, P.A., New York, NY, for Plaintiffs.

Carl Malmstrom, Wolf Haldenstein Adler Freeman & Herz LLC, Chicago, IL, for Plaintiff Hugh Robert Holmes.

James K. Langdon and Michael E. Rowe, Dorsey & Whitney LLP, Minneapolis, MN, Andrew R. Gray, Greenberg Traurig, LLP, Irvine, CA, Kehaulani R. Jai, Latham & Watkins LLP, Irvine, CA, Michele D. Johnson and Spencer L. Chatellier, Latham & Watkins LLP, Costa Mesa, CA, and Nicholas J. Siciliano, Latham & Watkins LLP, Chicago, IL, for Defendants.

Lead Plaintiffs David Carew and Hugh Robert Holmes brought this securities class action alleging that Defendants made materially false and misleading statements to stockholders. See generally ECF No. 42. The parties reached a settlement, which the Court has already preliminary approved, ECF No. 75, and Plaintiffs now move for final approval of that settlement, ECF No. 76. Plaintiffs also move for an award of attorneys’ fees, expenses, and service awards for the Class Representatives. ECF No. 78. Defendants do not oppose either motion, and class members have not objected. For the following reasons,

the motions are granted. BACKGROUND Plaintiffs are individuals who bought stock in Defendant Lifecore Biomedical, Inc. (“Lifecore”) between October 7, 2020, and March 19, 2024. ECF No. 42 ¶¶ 1, 42. Lifecore is a “diversified health and wellness company” that, until 2020, had two main components: Curation Foods and Lifecore Biomedical. Id. ¶ 2. Plaintiffs allege that between 2020 and

2023, Lifecore began to divest itself of its Curation Foods segment. Id. ¶ 3. But throughout this process, Plaintiffs allege, Lifecore misrepresented its financial status and, relevant here, the quality of its accounting processes. Id. ¶¶ 79–157. On March 20, 2024, Lifecore acknowledged in an SEC filing that it “did not design and operate effective internal controls” and detailed several “material weaknesses” in its internal controls and “material

errors” in its financial statements. Id. ¶ 158. Lifecore’s stock price consequently plummeted. Id. ¶¶ 158–61. Plaintiffs brought this action alleging that Lifecore’s series of misrepresentations caused Lifecore’s stock to be artificially inflated, and that its misrepresentations were in violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5. See id. ¶¶ 178–93. Plaintiffs also named Albert D. Bolles (Lifecore’s

CEO until August 2022), James G. Hall (Lifecore’s CEO after August 2022), Brian McLaughlin (Lifecore’s CFO until January 2021), and John Morberg (Lifecore’s CFO after January 2021) as Defendants. Id. ¶¶ 44–48. Defendants moved to dismiss on March 25, 2025. ECF No. 48. Plaintiffs responded. ECF No. 57. Before Defendants replied, the parties told the Court that they

were engaged in mediation and, as a result, asked for a stay. ECF No. 58. That mediation was unsuccessful, ECF No. 62, and Lifecore filed its reply, ECF No. 67. But a week before the scheduled hearing on the motion to dismiss, the parties told the Court that they had reached a settlement. ECF No. 68. Under the settlement agreement, Lifecore has deposited $3,750,000 into an escrow account, and following any deductions for attorneys’ fees, expenses, and service awards, the remaining settlement funds will be distributed to class

members. ECF No. 72-1 at 18; ECF No. 80 ¶ 61. That distribution will occur on a pro rata basis based on (i) the total number and value of claims submitted; (ii) when the individual claimant purchased or acquired Lifecore securities; and (iii) whether and when the claimant sold the Lifecore securities. ECF No. 80 ¶ 59; ECF No. 80-1 at 21. Plaintiffs moved for preliminary approval of the settlement, ECF No. 69, which the

Court granted, ECF No. 75. The Court set a final approval hearing for July 28, 2026. Id. at 3. On June 23, 2026, Plaintiffs moved for final approval of the settlement, ECF No. 76, and for attorneys’ fees, expenses, and service awards, ECF No. 78. Defendants represent that notice under the Class Action Fairness Act (“CAFA”) was served on all relevant authorities no later than January 27, 2026. ECF No. 85-1. Plaintiffs represent that

beginning on March 27, 2026, the Settlement Administrator sent notice by mail or email of the settlement to 24,370 potential class members, with additional efforts made at providing notice to those class members whose initial notices were deemed undeliverable. ECF No. 80-1 ¶¶ 3–10. The Settlement Administrator also gave notice by posting the settlement agreement, plan of allocation, class notice, complaint, and other important filings and deadlines in this case on various news journals and a publicly available website.

Id. ¶¶ 11–13. The deadline for objections was July 7, 2026. ECF No. 75 ¶ 11. Neither the Court nor the Settlement Administrator received any objections. ECF No. 80-1 ¶ 15. The Court held a final fairness hearing on July 28, 2026, at which Plaintiffs’ counsel discussed why the settlement was fair, reasonable, and adequate, and why Plaintiffs’ motion for attorneys’ fees, expenses, and service awards should be granted. ECF No. 83.

ANALYSIS I. Certification of the Settlement Class This Court provisionally granted class certification, and defined the proposed class as: All persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, and were damaged thereby.

Excluded from the Settlement Class are Defendants, the officers and directors of Lifecore at all relevant times, members of their immediate families and their legal representatives, heirs, successors, or assigns, any entity in which Defendants have or had a controlling interest, Legion Partners Asset Management, LLC, Wynnefield Capital, Inc., and 22NW, LP. Also excluded are any persons or entities who properly exclude themselves by filing a valid and timely request for exclusion in accordance with the requirements set by the Court.

ECF No. 75 at 2.

As for final approval, class certification is governed by Rule 23 of the Federal Rules of Civil Procedure, and a district court may not certify a class until it “is satisfied, after a rigorous analysis,” that Rule 23(a)’s certification prerequisites are met. Wal-Mart Stores, Inc. v. Dukes, 564 U.S. 338, 350–51 (2011) (citation omitted). To certify the proposed class, the Court must conclude that the four prerequisites of Rule 23(a) and at least one of

the provisions of Rule 23(b) are satisfied. See Comcast Corp. v. Behrend, 569 U.S. 27, 33 (2013). These requirements remain mandatory in the settlement context. See Kruger v. Lely N. Am., Inc., No. 20-cv-629 (KMM/DTS), 2023 WL 5665215, at *2 (D. Minn. Sep. 1, 2023). Here, a close review of the materials submitted in support of the unopposed motion, and other relevant materials in the case file, shows that the proposed settlement class

Free access — add to your briefcase to read the full text and ask questions with AI

David Carew and Hugh Robert Holmes, individually and on behalf of all others similarly situated v. LifeCore Biomedical, Inc.; Albert D. Bolles; James G. Hall; Brian McLaughlin; and John Morberg, (mnd 2026).

David Carew and Hugh Robert Holmes, individually and on behalf of all others similarly situated v. LifeCore Biomedical, Inc.; Albert D. Bolles; James G. Hall; Brian McLaughlin; and John Morberg (David Carew and Hugh Robert Holmes, individually and on behalf of all others similarly situated v. LifeCore Biomedical, Inc.; Albert D. Bolles; James G. Hall; Brian McLaughlin; and John Morberg) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Boeing Co. v. Van Gemert
444 U.S. 472 (Supreme Court, 1980)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Matrixx Initiatives, Inc. v. Siracusano
131 S. Ct. 1309 (Supreme Court, 2011)
Erica P. John Fund, Inc. v. Halliburton Co.
131 S. Ct. 2179 (Supreme Court, 2011)
Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
Comcast Corp. v. Behrend
133 S. Ct. 1426 (Supreme Court, 2013)
Oscar Ortega v. Uponor, Inc.
716 F.3d 1057 (Eighth Circuit, 2013)
Zilhaver v. UnitedHealth Group, Inc.
646 F. Supp. 2d 1075 (D. Minnesota, 2009)
In Re Omnivision Technologies, Inc.
559 F. Supp. 2d 1036 (N.D. California, 2008)
Yarrington v. SOLVAY PHARMACEUTICALS, INC.
697 F. Supp. 2d 1057 (D. Minnesota, 2010)
Laura Powers v. Credit Management Services, In
776 F.3d 567 (Eighth Circuit, 2015)
Kenneth Njema v. Wells Fargo Bank, N.A.
847 F.3d 934 (Eighth Circuit, 2017)
Alexia Keil v. Paul Lopez
862 F.3d 685 (Eighth Circuit, 2017)
Lorence v. U.S. Bank National Ass'n
291 F.3d 1035 (Eighth Circuit, 2002)